

Market Data

Nexalin Technology, Inc. Nasdaq: NXL

Fiscal Year	Dec. 31
Price	\$1.16
Market Cap	\$8.6M
Shares Out.	7.4M
Float	5.7M
Avg. Vol. (90-day)	582,307
Revenue (ttm)	\$0.1M
Cash (mrq)	\$3.0M

Price & share data as of May 9, 2024

Auditor:

Marcum LLP

Legal Counsel:

Warshaw Burstein LLP

Transfer Agent:

Continental Stock Transfer & Trust

nexalin.com



Gen-3 Headset

Nexalin uses proprietary single-use electrodes to deliver an undetectable proprietary frequency-based waveform with lifetime recurring revenue.

Company Overview

Nexalin Technology is a pioneering medical technology company focused on addressing the global mental health crisis through innovative neurostimulation devices. Nexalin's products, which include the Gen-2 and newly introduced Gen-3 HALO™ Clarity devices, are non-invasive and utilize advanced frequency-based stimulation to target deep brain structures associated with various mental health disorders. These disorders include but are not limited to depression, anxiety, insomnia, PTSD, and traumatic brain injuries. Nexalin's commitment to non-pharmacological treatment options is underpinned by extensive clinical research and intellectual property protections, aiming to provide significant therapeutic benefits without adverse effects. The company's approach integrates product innovation with a virtual clinic model to enhance accessibility and effectiveness of treatments, offering a significant step forward in mental healthcare.

Investment Highlights

Innovative technology with proven clinical results

- Pioneering non-invasive, frequency-based deep brain stimulation devices targeting treatment-resistant mental health disorders including PTSD, insomnia, depression, and more
- Demonstrated improvements in sleep quality and mental health parameters, substantiated by multiple peer-reviewed studies
- Positive outcomes from studies conducted at University of California, San Diego showing effectiveness in reducing PTSD and post-concussive symptoms

Strategically positioned to address massive market opportunity

- Mental health market projected to reach \$537 billion by 2030
- Recent market entry into the Middle East, with plans to expand into additional international markets
- Regulatory approvals in Oman and China
- FDA approval process underway
- Committed to maintaining operational efficiency while scaling up production and clinical deployment

Strong intellectual property protections

- Robust IP portfolio with several patents issued and pending, protecting core technologies through 2040

Experienced leadership and advisory board

- Led by CEO Mark White, a pioneer in digital medical markets with direct experience in neuro-stimulation technologies
- Core executive team includes Dr. David Owens (CMO) and Marilyn Elson (CFO), who together bring decades of experience in medical technology, clinical operations, and financial management
- Supported by an advisory board with deep expertise in investment banking, global strategy, and product development

Global Mental Health Epidemic



Insomnia

Almost 40 million Americans suffer from chronic insomnia (NCBI). 40% of people with insomnia are believed to also be affected by a mental health disorder.

***Nexalin Gen-1 devices obtained FDA clearance for Insomnia. In December 2019, FDA required new amended 510K applications for insomnia. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Insomnia.*



Anxiety

Anxiety disorders are common, affecting about 18 percent of adults. But only about a third seek treatment. (Anxiety and Depression Assoc. of America).

***Nexalin Gen-1 devices obtained FDA clearance for Anxiety. In December 2019, FDA required new amended 510K applications for Anxiety. Nexalin is presently analyzing prior FDA applications to determine new regulatory strategies for the treatment of Anxiety.*



Dementia and Depression

An estimated 6.2 million Americans aged 65 and older are living with Alzheimer's Dementia in 2021 (alz.org). Experts estimate that up to 40 percent of people with Alzheimer's disease suffer from significant depression. (Alzheimer's Assoc.)

****Nexalin is in the planning process to submit applications for FDA clearance for the treatment of Depression and Mild Dementia Disorder.*



Addiction

Approximately 20 million Americans battled some form of substance abuse each year, prior to the additional challenge of Covid-19. (NSDUH)

**** Nexalin is in the planning process to submit applications for FDA clearance for the treatment of Addiction and Substance Use Disorder.*

Value Proposition

Nexalin Technology stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO™ Clarity, offer a groundbreaking alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limited effective treatments—positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach \$537 billion by 2030.

Recent strategic developments, such as the introduction of the Virtual Clinic, allow patients to receive treatment from the comfort of their homes, thereby enhancing Nexalin's market differentiation and patient accessibility. Combined with the robust expansion of the Company's intellectual property portfolio and regulatory approvals in multiple countries, these developments broaden Nexalin's market presence and are expected to drive sustained shareholder value improvement. Nexalin offers investors an opportunity to invest in a company that is not just prepared for the future but is actively shaping it, offering a profound chance to improve mental health outcomes on a global scale.

Global Funded Clinical Trials in Process



首都医科大学宣武医院
Xuanwu Hospital Capital Medical University

UC San Diego

Penn
UNIVERSITY OF PENNSYLVANIA